PROVIDENCE, R.I. (March 23, 2022) — Brown Surgical Associates today announced it is welcoming fellowship-trained surgeon and researcher Steven C. Katz, M.D., FACS to the practice’s Division of Surgical Oncology.
Experienced in both the operating room and research lab, Dr. Katz is a true innovator in his field. His clinical practice is focused on melanoma, sarcoma, and other complex, rare soft-tissue tumors. As the Chief Medical Officer of TriSalus Life Sciences – a Rhode Island and Colorado-based biotech company – his laboratory research endeavors focus on developing novel immunotherapy approaches for liver and pancreas tumors.
“With the belief that medicine reaches far beyond the operating room, it’s important to us that all Brown Surgical Associates surgeons – in addition to being doctors – are also teachers, researchers, and innovators. Dr. Katz fits that bill to a tee,” said Dr. William Cioffi, president of Brown Surgical Associates. “Not only is he treating the patients of today, but he’s also developing the treatments of tomorrow. His experience and knowledge will help ensure we continue to provide world-class surgical care to the people of Rhode Island, Southeastern Massachusetts, and beyond.”
Dr. Katz’s overarching career goal is to develop novel immunotherapy treatments for presently incurable liver and pancreas tumors.
“It is a true privilege to join Brown Surgical Associates and be part of a world-class team. I have long admired the leadership and its commitment to serving patients in need of surgical care, in addition to ensuring outstanding medical education programs,” Dr. Katz said. “I look forward to making meaningful contributions in the clinical and academic arenas, including helping the team to provide innovative treatment options which may not be available elsewhere in our region.”
Dr. Katz attended New York University School of Medicine, receiving the Alpha Omega Alpha Award for graduating with the top academic average in his class. He then completed his general surgery residency at the New York University Medical Center. Dr. Katz went on to complete fellowships in immunology and surgical oncology at Memorial Sloan-Kettering Cancer Center, where he served as the chief administrative fellow. As a researcher, he has served as the principal investigator for five solid tumor CAR-T trials, including four for liver metastases and one for peritoneal carcinomatosis. Dr. Katz has developed numerous cell therapy products and methods for solid tumor immunotherapy. He has received research grants from numerous societies, the National Institute of Health, and the Department of Defense, in addition to multiple industry partners.